Grifin Tablets (Pioglitazone Hydrochloride)

Adult dose

This medication is taken orally once daily, regardless of meals. As monotherapy, it is initiated at a dose of 15 mg once daily; if enough efficacy is not achieved, it may be increased to 30 mg once daily. In combination therapy, it is also administered at 15 mg once daily, and the maximum recommended dose should not exceed 30 mg once daily.

Child dose

There is no experience using this medication in patients under 18 years old; therefore, administration is not recommended.

This medication is used for the treatment of type 2 diabetes and requires the presence of insulin to be effective. This medication may cause or worsen heart failure; therefore, it should not be used in patients with heart failure. After starting treatment or increasing the dose, careful observation for symptoms of heart failure, such as weight changes, shortness of breath, and edema, is necessary. If symptoms of heart failure occur, immediate medical attention should be sought, and if necessary, the administration of this medication can be reduced or discontinued. Furthermore, this medicine can cause fluid retention, which may induce or exacerbate heart failure, so it should be used cautiously in patients with edema or heart diseases. Patients with active bladder cancer or a history of bladder cancer, liver diseases, severe kidney diseases, or diabetic ketoacidosis should not use this medication. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women may require appropriate contraception due to the possibility of ovulation stimulation while taking this medicine. Regular monitoring of blood sugar and liver function tests is required during treatment with this medication, and immediate consultation with a physician should be sought if abnormal symptoms occur. This medication has a risk of hypoglycemia when used in combination with other hypoglycemic agents, so caution regarding dosage adjustment is necessary. Additionally, this medication may cause weight gain and edema, thus careful monitoring of weight changes is essential. In clinical trials and post-marketing surveys, rare side effects such as liver failure, macular edema, and fractures have been reported, so if any related symptoms occur, immediate notification to healthcare providers is necessary. This medication has drug interactions; therefore, it is crucial to inform healthcare providers if other medications are being taken, especially when used with CYP2C8 inhibitors or inducers. In case of overdose, there is no specific antidote, and symptomatic supportive care is needed. Store this medication out of reach of children and keep it in the original container. This medication has not been established for safety and efficacy in children under 18 years old, and caution is advised in patients aged 75 and older.

Serious side effects

Congestive heart failure, worsening heart failure, severe heart failure, cardiovascular abnormalities, myocardial infarction, stroke, edema (including severe edema, systemic edema, and fluid retention), death due to cardiovascular predisposition, cardiac function loss, numbness, hypoglycemia (including hospitalization for severe hypoglycemia), liver failure, liver damage (associated with elevated ALT and bilirubin), bladder cancer, urticaria, severe allergic reactions, severe swelling (edema),

Mild side effects

• Headache
• sinusitis
• muscle pain
• pharyngitis
• abdominal distension
• weight gain
• upper respiratory tract infection
• hypoglycemia
• urinary tract infection
• back pain

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature. This way, the medication's effectiveness and safety can be preserved for a long time.

Appearance

White, round tablets

Package unit

30 tablets/bottle, 300 tablets/bottle